Department of Internal Medicine, Section on Pulmonary and Critical Care Medicine, Wake Forest Baptist Hospital, Winston-Salem, NC, USA.
Department of Internal Medicine, Section on Pulmonary, Critical Care and Sleep Medicine, W. G. (Bill) Hefner Veterans Affairs Medical Center, Salisbury, NC, USA.
Curr Allergy Asthma Rep. 2021 Feb 9;21(2):9. doi: 10.1007/s11882-020-00985-7.
Cystic fibrosis (CF) is a multisystem, autosomal recessive disease that leads to progressive loss of lung function. Respiratory symptoms for both CF and asthma include cough, wheezing, and dyspnea. There is debate within the CF community on how to best define and distinguish CF-asthma overlap syndrome (CFAOS) from asthma-like features, though CFAOS is well-recognized. We aim to review the epidemiology, diagnosis, and treatment of asthma in CF and explore areas where further research is needed.
There has been considerable improvement in the understanding and treatment of asthma over the past two decades leading to novel therapies such as biologic agents that target the airway inflammation in asthmatics based on their asthma phenotype. These therapies are being studied in CFAOS and are promising treatments. This review provides a comprehensive overview of the definition, epidemiology, diagnosis, and current treatment of CFAOS.
囊性纤维化(CF)是一种多系统、常染色体隐性遗传病,可导致肺功能进行性丧失。CF 和哮喘的呼吸系统症状均包括咳嗽、喘息和呼吸困难。CF 患者群体内部对于如何最好地定义和区分 CF-哮喘重叠综合征(CFAOS)与哮喘样特征存在争议,但 CFAOS 是公认的。我们旨在综述 CF 中的哮喘流行病学、诊断和治疗,并探讨需要进一步研究的领域。
在过去二十年中,哮喘的认识和治疗取得了相当大的进展,出现了新型疗法,例如针对哮喘表型的气道炎症的生物制剂等。这些疗法正在 CFAOS 中进行研究,具有广阔的应用前景。本综述全面概述了 CFAOS 的定义、流行病学、诊断和当前治疗。